Impact of antiviral treatment on long-term prognosis in non-immunocompromised patients with CMV reactivation

Reactivation of human cytomegalovirus (CMV) occurs in non-immunocompromised patients with or without specific organ involvement, but it is still unknown whether it has a clinical implication on long-term prognosis or not. A retrospective cohort study evaluating non-immunocompromised adult patients w...

Full description

Saved in:
Bibliographic Details
Published in:BMC infectious diseases 2021-05, Vol.21 (1), p.414-414, Article 414
Main Authors: Park, Ga Eun, Ki, Hyun Kyun, Ko, Jae-Hoon
Format: Article
Language:English
Subjects:
Antiviral drugs
Bacterial infections
Cytomegalovirus
Disease
Drug dosages
Ganciclovir
Genetic testing
HIV
Hospitalization
Hospitals
Human immunodeficiency virus
Illnesses
Immunocompromised hosts
Infections
Length of stay
Long-term
Medical prognosis
Mortality
Multivariate analysis
Pathogens
Patients
Prognosis
Reactivation
Survival
Ventilators
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Reactivation of human cytomegalovirus (CMV) occurs in non-immunocompromised patients with or without specific organ involvement, but it is still unknown whether it has a clinical implication on long-term prognosis or not. A retrospective cohort study evaluating non-immunocompromised adult patients with CMV reactivation was conducted during the period between January 2010 and February 2018. Patients were divided into ganciclovir-treated and non-treated groups. Patients who died within 30 days from CMV reactivation were excluded as they died from complex causes of conditions. Survivors were followed for 30-months to evaluate long-term prognosis. A total of 136 patients with CMV reactivation was included, consisting of 66 ganciclovir-treated (48.5%) and 70 non-treated (51.5%) patients. Overall, patients were old-aged (median 70 years old) and most were treated with pneumonia of any cause (91.2%). More patients in ganciclovir-treated group were treated at intensive care unit (43.9% vs 24.3%, respectively) and had higher viral load over 5000 copies/ml (48.5% vs 22.9%) than non-treated group (all P 
ISSN:1471-2334
1471-2334
DOI:10.1186/s12879-021-06098-4